



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Dated:14.02.2022

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Monday, 14th February 2022 **at 05:00 p.m. and concluded at 06:40 p.m.** discussed the following business: -

1. Appointment of Shri K Vinay Kumar, Independent Director(DIN: 02322747) as Chairman of the Company.
2. Approved Un-audited Financial Results for the Quarter ended 31st December 2021.
3. Approved and took decision on conversion of the 02nd Tranch of 8,89,667 nos of Equity warrants into Equity Shares at Rs 20.69 per Shares as per the sanction given by BSE dated 26th March 2021 asking the allottees to bring 02nd Tranche subscription money.
4. Consider and Approved incorporating a wholly owned Subsidiary Company of Sandu Pharmaceuticals Limited.

You are requested to kindly take the same on record.

Yours Faithfully,

For Sandu Pharmaceuticals Limited

Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587



Sandu Pharmaceuticals Ltd

STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 31/12/21

(Rs in Lakhs)

	Particulars	Quarter ended			Nine Months ended		Year Ended 31-03-2021
		Quarter Ended 31-12-2021	Quarter Ended 30-09-2021	Quarter Ended 31-12-2020	Nine months Ended 31-12-2021	Nine months Ended 31-12-2020	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I	Revenue From Operations	1,915.01	1,759.04	1,576.88	5,407.65	4,466.00	5,875.54
II	Other Income	0.37	2.78	7.19	5.50	16.26	19.34
III	Total Income (I+II)	1,915.38	1,761.82	1,584.07	5,413.15	4,482.26	5,894.88
IV	EXPENSES						
	Cost of materials consumed	336.35	539.73	325.08	1,135.73	821.73	1,187.18
	Purchases of Stock-in-Trade	834.50	645.12	536.50	2,156.58	1,282.79	1,924.13
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(47.18)	(184.22)	(44.50)	(83.37)	654.56	338.70
	Employee benefits expense	234.42	256.19	319.89	707.47	657.93	801.82
	Finance costs	0.28	4.80	1.39	8.92	5.72	11.49
	Depreciation and amortization expense	13.38	13.31	14.10	39.89	41.86	55.67
	Other expenses	480.42	421.84	389.80	1,261.23	915.29	1,407.80
	Total expenses (IV)	1,852.16	1,696.77	1,542.26	5,226.44	4,379.88	5,726.79
V	Profit/(loss) before exceptional items and tax (I-IV)	63.22	65.05	41.81	186.71	102.38	168.09
VI	Exceptional Items					-	-
VII	Profit/(loss) before tax (V-VI)	63.22	65.05	41.81	186.71	102.38	168.09
	Tax expense:					-	-
VIII	(1) Current tax	18.59	20.03	12.28	54.91	28.93	55.71
	(2) Deferred tax	(0.26)	(0.28)	0.20	(0.17)	0.65	2.95
	(3) Short / Excess Provision						0.18
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	44.88	45.30	29.33	131.98	72.80	109.25
X	Profit/(loss) for the period (IX+XII)	44.88	45.30	29.33	131.98	72.80	109.25
XI	Other Comprehensive Income						
	Items that will not be reclassified to Profit & Loss					-	1.90
	Fair value changes of investments	9.58	13.74	23.74	29.31	46.29	58.30
	Income tax relating to items that will not be reclassified to Profit & Loss account.	(1.07)	(1.53)	(2.47)	(3.26)	(4.81)	(7.79)
XII	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	53.40	57.51	50.60	158.02	114.28	161.66
						-	-
XIV	Paid Up Equity Capital (Face Value of Rs 10/- Per share)	792.09	792.09	708.10	792.09	708.10	708.10
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.57	0.57	0.41	1.67	1.03	1.54
	(2) Diluted	0.48	0.49	0.41	1.47	1.03	1.54

Mumbai
Date :- 14.02.2022

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141



Regd. & Factory Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in


CIN:L24233GA1985PLC001587

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 14th February 2022. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Company has considered the possible impact of COVID-19 pandemic on its operations, liquidity position and recoverability of its asset balances at 31st December, 2021 based on the internal and external information upto the date of approval of these financial results. The impact of COVID-19 may be different from that estimated as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the Company and take necessary measures to address the situation.
3. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
4. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 14th February, 2022. there are no qualifications in the limited review report issued for the nine months & quarter ended December 2021.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary

Place: - Mumbai

Date: - 14/02/2022

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Managing Director
DIN :- 01132141





Dileep & Prithvi

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2021, PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,

**The Board of Directors,
Sandu Pharmaceuticals Limited,
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.**

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and nine months ended on 31st Dec, 2021, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi

Chartered Accountants


Firm Registration Number: 122290W

Himmat Mali

(Partner)

Membership Number: 183378

UDIN-22183378ABZLYS2722



Place: Mumbai

Date: 14th February, 2022

4-A, 3rd Floor, Dahanukar Bldg., 480, Kalbadevi Road, Mumbai - 400 002. • Tel.: +91-22-22071185 / 40031184 • E-mail : contact@dileepprithvi.com

Web.: www.dileepprithvi.com